Economic value of dengue vaccine in Thailand

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 5, 2011, Pages 764-772

  Lee, Bruce Y ^a,b,c   Connor, Diana L ^a,b,c   Kitchen, Sarah B ^a,b,c   Bacon, Kristina M ^a,b,c   Shah, Mirat ^a,b,c   Brown, Shawn T ^c,d   Bailey, Rachel R ^a,b,c   Laosiritaworn, Yongjua ^c   Burke, Donald S ^c   Cummings, Derek A T ^e  

^a Public Health Computational and Operations Research (PHICOR)   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d PITTSBURGH SUPERCOMPUTING CENTER   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DENGUE; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; GROSS NATIONAL PRODUCT; HELP SEEKING BEHAVIOR; HUMAN; PROBABILITY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION; THAILAND;

COST-BENEFIT ANALYSIS; DENGUE; DENGUE VACCINES; HUMANS; THAILAND;

EID: 79958715836     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.10-0624     Document Type: Article

References (43)

1. Pediatric Dengue Vaccine Initiative, 2009. Global Burden of Disease. Available at : http://www.pdvi.org/about-dengue/GBD.asp. Accessed December 20, 2010.
2. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI, 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22: 1275-1280. (Pubitemid 38296672)
3. Nagao Y, Koelle K, 2008. Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proc Natl Acad Sci USA 105: 2238-2243. (Pubitemid 351439495)
4. Suaya JA, Shepard DS, Chang MS, Caram M, Hoyer S, Socheat D, Chantha N, Nathan MB, 2007. Cost-effectiveness of annual targeted larviciding campaigns in Cambodia against the dengue vector Aedes aegypti. Trop Med Int Health 12: 1026-1036. (Pubitemid 47414941)
5. Lambrechts L, Scott TW, Gubler DJ, 2010. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis 4: e646.
6. Chikaki E, Ishikawa H, 2009. A dengue transmission model in Thailand considering sequential infections with all four serotypes. J Infect Dev Ctries 3: 711-722.
7. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, Yoon IK, Jarman RG, Green S, Rothman AL, Cummings DA, 2010. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 4: e617.
8. Halstead SB, Nimmannitya S, Cohen SN, 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311-328.
9. Burke DS, Nisalak A, Johnson DE, Scott RM, 1988. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172-180. (Pubitemid 18036130)
10. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB, 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-669. (Pubitemid 15210730)
11. Durbin AP, Whitehead SS, 2010. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 338: 129-143.
12. Webster DP, Farrar J, Rowland-Jones S, 2009. Progress towards a dengue vaccine. Lancet Infect Dis 9: 678-687.
13. Lang J, 2009. Recent progress on Sanofi Pasteur's dengue vaccine candidate. J Clin Virol 46 (Suppl 2): S20-S24.
14. Sanofi-Aventis Study of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects, 2008. Available at: http://clinicaltrials.gov/ct2/show/NCT00730288. NLM Identifier NCT00730288. Accessed August 17, 2010.
15. Voelker R, 2010. Race is on for effective dengue vaccine. JAMA 304: 1430-1431.
16. Lee BY, Burke DS, 2010. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28: 2806-2809.
17. Baly A, Toledo ME, Boelaert M, Reyes A, Vanlerberghe V, Ceballos E, Carvajal M, Maso R, La Rosa M, Denis O, Van der Stuyft P, 2007. Cost effectiveness of Aedes aegypti control programmes: participatory versus vertical. Trans R Soc Trop Med Hyg 101: 578-586. (Pubitemid 46620663)
18. McConnell KJ, Gubler DJ, 2003. Guidelines on the cost-effectiveness of larval control programs to reduce dengue transmission in Puerto Rico. Rev Panam Salud Publica 14: 9-16. (Pubitemid 37033773)
19. Kliks SC, Nimmanitya S, Nisalak A, Burke DS, 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411-419. (Pubitemid 18086128)
20. World Health Organization, 2008. Global Health Observatory. Available at : http://apps.who.int/ghodata/?vid=720. Accessed October 20, 2010.
21. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L, 1990. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 42: 179-184. (Pubitemid 20093452)
22. Bureau of Epidemiology, 2009. Bureau of Epidemiology. Available at: http://epid.moph.go.th/http://epid.moph.go.th. Accessed May 21, 2010.
23. Vellozzi C, Mitchell T, Miller E, Casey CG, Eidex RB, Hayes EB, 2006. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg 75: 333-336. (Pubitemid 46941356)
24. Centers for Disease Control and Prevention, 2004. Yellow Fever Vaccine: What You Need to Know. Atlanta, GA : Centers for Disease Control and Prevention.
25. Centers for Disease Control and Prevention, 2010. Japanese Encephalitis Vaccine: What You Need to Know. Atlanta, GA: Centers for Disease Control and Prevention, 2.
26. Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL, Green S, Vaughn DW, Ennis FA, Endy TP, 2007. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 369: 1452-1459. (Pubitemid 46635782)
27. World Health Organization, 2004. Global Burden of Disease 2004 Update: World Health Organization, 9. Geneva: WHO.
28. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, Kongsin S, Jiamton S, Garrido F, Montoya R, Armien B, Huy R, Castillo L, Caram M, Sah BK, Sughayyar R, Tyo KR, Halstead SB, 2009. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 80: 846-855.
29. Guzman MG, Kouri G, Morier L, Soler M, Fernandez A, 1984. A study of fatal hemorrhagic dengue cases in Cuba, 1981. Bull Pan Am Health Organ 18: 213-220.
30. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370-377.
31. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, Gailhardou S, Boaz M, Feroldi E, 2010. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 29: 1111-1117.
32. Torresi J, McCarthy K, Feroldi E, Meric C, 2010. Immunogenicity, safety and tolerability in adults of a new single-dose, liveattenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine 28: 7993-8000.
33. Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M, 2010. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: Randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin 6: 906-914.
34. World Health Organization, 2009. Choosing Interventions that are Cost Effective (WHO-CHOICE): Cost-effectiveness thresholds. Available at: http://www.who.int/choice/costs/CER-thresholds/en/index.html. Accessed October 20, 2010.
35. The World Bank, 2010. Data : GDP per capita (current US$). Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed July 10, 2010.
36. Initiative for Vaccine Research, 2008. WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. Geneva: World Health Organization, Department of Immunization Vaccines and Biologicals.
37. Gold MR, 1996. Cost-effectiveness in health and medicine. New York: Oxford University Press.
38. Dollar US, (USD) to Thai Baht (THB) exchange rate history. Available at : http://www.exchangerates.org.uk/USD-THBexchange-rate-history.html. Accessed October 28, 2010.
39. Wolfson LJ, Gasse F, Lee-Martin SP, Lydon P, Magan A, Tibouti A, Johns B, Hutubessy R, Salama P, Okwo-Bele JM, 2008. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ 86: 27-39.
40. National Institute of Allergy and Infectious Diseases (NIAID), 2010. Evaluation of the safety and immune response of three admixtures of a tetravalent dengue virus vaccine. Available at: http://ClinicalTrials.gov/show/ NCT01072786 NLM Identifier NCT01072786. Accessed September 29, 2010.
41. Lee BY, McGlone SM, 2010. Pricing of new vaccines. Hum Vaccin 6: 619-626.
42. World Health Organization, 2010. WHO-UNICEF estimates of immunization coverage: the Kingdom of Thailand. Available at : http://apps.who.int/ immunization-monitoring/en/globalsummary/timeseries/tswucoveragebycountry.cfm? country=THA. Accessed September 20, 2010.
43. UNICEF, 2008. Thailand Statistics. Available at : www.unicef.org/ infobycountry/Thailand.statistics.html. Accessed October 2, 2010.